Visit our UK website
Memory Care Specialists
New Treatments to Slow Alzheimer's Available Now
As global leaders in Alzheimer’s research, we are highly experienced in providing new generation therapies for Alzheimer’s Disease. We are now offering Kisunla™ and Leqembi™ to patients who are covered by Medicare and major insurers. Learn how we can support you on your Alzheimer’s journey today.
"*" indicates required fields
Explore the Page:
Medicare Covers these New Medications
Contact us for more information. Call Now: 1 888-437-0813
The Latest in Breakthrough Treatments for Alzheimer’s
Making a real change in any disease requires not only new revolutionary medications, but also the ability to detect the disease at the earliest possible moment. At Re:Cognition Health, we are providing early diagnosis and quick access to new treatments that will slow, stop, and eventually prevent the onset and progression of symptoms.
New amyloid targeting therapies have recently been approved for Alzheimer’s patients. At Re:Cognition Health’s centers, we can now prescribe medication, such as Kisunla™ and Leqembi™ for Alzheimer’s Disease. The new medications are covered by Medicare and major insurers. Get quick and easy access to our specialists. Contact us today about your diagnosis and treatment of Alzheimer’s.
What are the new amyloid targeting therapies for Alzheimer’s Disease?
Kisunla™ and Leqembi™ are monoclonal antibodies designed to target and clear amyloid-beta plaques in the brain, a hallmark of Alzheimer’s. By reducing these toxic proteins, they help slow cognitive decline and disease progression, offering hope for patients in the early stages of the condition.
Learn more about Leqembi™
Click Here.
And learn more about Kisunla™
Click Here.
Who is eligible for these drugs?
Call us today to discuss if you or a loved one are suitable for Kisunla™ or Leqembi™
- Eligibility: Confirmation of elevated amyloid protein by Amyloid PET or CSF analysis is mandatory.
- Treatment: Bi-weekly intravenous infusion (Leqembi™) or monthly intravenous infusion (Kisunla™) with monitoring via MRI scans.
- Required: A program partner (family member or friend) for regular contact.
- Follow-Up: Recommended amyloid re-assessment at 12 months, then at 18 or 24 months.
How soon can I be seen?
At Re:Cognition Health we know how important early detection is so we do not have lengthy waiting lists. We get prospective patients screened as soon as possible. In most cases, we see new patients within a week for an assessment and schedule a follow-up appointment immediately afterwards.
Will insurance cover these new medications?
Both Alzheimer’s medications are covered by Medicare and all major commercial insurers.
Call us today to check your coverage.
Diane and Gary Reedy Share Their Journey
Diane and Gary share their journey with Re:Cognition Health.
Understanding Amyloid Related Imaging Abnormalities (ARIA)
ARIA is a known side-effect of these medications, but it can be effectively controlled through proper oversight. Dr. Emer MacSweeney, Consultant Neuroradiologist and CEO of Re:Cognition Health provides further insight into ARIA.